Synergism and Antagonism in Chemotherapy
This book provides a practical, mechanism-oriented coverage of beneficial chemotherapeutic drug interactions in the clinic and in experimental model systems. Anticancer, antimicrobial, and antiviral systems are included, as well as methodology for characterization and quantitation of synergism and antagonism. An overview chapter integrates diverse aspects of the field, and individual chapters give unique and timely treatment of specific topics. This book will be a useful tool for those interested in drug combination design because it reviews mechanistic information on both combinations of experimental agents and drugs used clinically. It is intended for students, clinicians, and researchers in medicine, pharmacology, chemistry, and biochemistry.
- Hardback | 640 pages
- 166.9 x 231.9 x 28.2mm | 1,165.73g
- 01 Mar 1991
- Elsevier Science Publishing Co Inc
- Academic Press Inc
- San Diego, United States
Table of contents
Part 1 Reviews and methods of quantitation: synergism, antagonism and potentiation in chemotherapy - an overview, D.Rideout and T.-C.Chou; the median effect principle and the combination index as tools for quantitation of synergism and antagonism, T.-C.Chou; clinical studies of combination chemotherapy for cancer, E.Frei; combined chemotherapeutic modalities for viral infections - rational and clinical potential, R.F.Schinazi; antimalarial synergism and antagonism, J.L.Vennerston, et al; quantitation of synergism and antagonism of two or more drugs by computerized analysis, J.Chou. Part 2 Mechanisms of interaction: potentiation through inhibition of metabolic drug inactivation - modulation of drug activity and toxicity by perturbation of glutathione metabolism, H.S.Friedman and O.W.Griffith; synergy and antagonism in polymerase-targeted antiviral therapy - effects of deoxynucleoside triphosphate pool modulation on prodrug activation, T.Spector and J.A.Fyfe; reversal of multidrug resistance in tumour cells, C.-P.H.Yang, et al; biochemical mechanism of the synergistic interaction of antifolates acting on different enzymes of folate metabolic pathways, J.Galivan; synergistic and antagonistic drug interactions resulting from multiple inhibition of metabolic pathways, R.C.Jackson; enhanced effects of drugs that bind simultaneously to the same macromolecular target, L.Strekowski and W.D.Wilson; modulation of 5-fluorouracil by metabolites and antimetabolites, E.Mini and J.R.Bertino; synergism and antagonism through direct bond formation between two agents in situ, D.C.Rideout and T.Calogeropoulou; chemotherapeutic potentiation through interaction at the level of DNA, B.A.Teicher, et al; drug synergism, antagonsim and collateral sensitivity involving genetic changes, S.-H.Huang and J.S.Holcenberg. Part 3 Condition-selective synergism and antagonism: schedule-dependent effects in antineoplastic synergism and antagonsim, B.K.Chang; effects of drug distribution and cellular microenvironment on the interaction of cancer chemotherapeutic agents, R.E.Durrand; synergistic interactions at the solid tumour level through targeting of therapies against two or more different tumour cell subpopulations, D.W.Siemann and P.C.Keng; selective synergism aganist the target versus host bone marrow progenitor cells, E.Berman and T.-T.Chang.